| Ytd | 73.82% | |
| 1y | 121.83% |
| Open | 17.96 | Prev Close | 18.06 | Low | 17.91 | High | 18.23 | Mkt Cap | 1.11B |
| Vol | 130.45K | Avg Vol | 1.06M | EPS | -3.36 | P/E | -5.37 | Forward P/E | 6.74 |
| Beta | -0.01 | Short Ratio | 7.24 | Inst. Own | 107.69% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 15.99 | 200-d Avg | 12.62 | 1yr Est | 31.55 |
CGEM News
Cullinan Therapeutics remains a compelling buy as zipalertinib approaches a key FDA decision for EGF
Cullinan Therapeutics, Inc. (CGEM) Discusses Promising Clinical Data for CLN-978 and Velinotamig in
CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both
href=https://www.benzinga.com/quote/RMSG target=_blank>(NASDAQ: RMSG) lost 67.6% to $0.69 in
Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and
New and updated clinical data to be presented from over 30 patients across systemic lupus erythemato
Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to ad
CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a cl
MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discov
Initial clinical data in SLE and RA for CLN-978, a CD19 T cell engager, to be presented at the EULAR
Global Business Travel Group Inc (GBTG), a NYSE-listed company, saw its stock rise 57% on Monday af
Cullinan Therapeutics's Zipalertinib NDA has been accepted, making its February 27, 2027, PDUFA date
PRINCETON, N.J. & TOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taiho Oncology, Inc., Taiho Pharmaceuti
Genprex (NASDAQ: GNPX - Get Free Report) and Cullinan Therapeutics (NASDAQ: CGEM - Get Free Report)
Cullinan Therapeutics (NASDAQ: CGEM) outlined a milestone-heavy roadmap during a presentation at Lee
Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA conf
Cullinan Therapeutics (NASDAQ: CGEM) executives highlighted upcoming clinical milestones for the com
Cullinan Therapeutics, Inc. (NASDAQ: CGEM - Get Free Report) CEO Nadim Ahmed sold 16,381 shares of t
Cullinan Therapeutics, Inc. (NASDAQ: CGEM - Get Free Report) insider Jennifer Michaelson sold 11,742
CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cull
Cullinan Therapeutics is rated a Buy, driven by a robust T-cell engager pipeline, savvy management,
Cullinan Therapeutics, Inc. (CGEM) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transc
During Thursday, 849 stocks hit new 52-week lows.
On Monday, 147 stocks hit new 52-week lows.